-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56

Benzinga·10/29/2025 19:50:53
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $54 to $56.